Investment Thesis
Sensei Biotherapeutics is a pre-revenue biopharmaceutical company with negative stockholders' equity of -$137.3M, indicating balance sheet insolvency despite adequate cash reserves. The company is burning $10.7M in operating cash flow quarterly with no revenue generation, resulting in -$170.6M operating losses. While the cash position provides 3-4 years of runway, the lack of commercial revenue, significant losses, and negative equity position present substantial financial risk.
Strengths
- Strong cash position of $152.3M providing 3-4 year runway at current burn rate
- Minimal debt burden ($567.0K long-term debt) with low leverage risk
- High liquidity ratios (14.39x current and quick ratios) enabling operational flexibility
Risks
- Negative stockholders' equity of -$137.3M indicates balance sheet insolvency and technical bankruptcy risk
- Pre-revenue stage with no commercial product generation, entirely dependent on clinical development success
- Significant quarterly cash burn of $10.7M with no offsetting revenue, requiring continuous capital raises or successful product launches
Key Metrics to Watch
- Clinical trial progress and regulatory milestones for lead pipeline candidates
- Cash runway depletion rate and timing of capital requirements for clinical programs
- Path to revenue generation or partnership announcements providing commercialization validation
Financial Metrics
Revenue
N/A
Net Income
-170.2M
EPS (Diluted)
$-131.45
Free Cash Flow
-10.7M
Total Assets
205.4M
Cash
152.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-82.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
14.39x
Quick Ratio
14.39x
Debt/Equity
N/A
Debt/Assets
6.9%
Interest Coverage
-5,332.09x
Long-term Debt
567.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T06:56:51.994985 |
Data as of: 2026-03-31 |
Powered by Claude AI